Amiodarone-sirolimus/tacrolimus interaction in a pediatric heart transplant patient

Pediatric Transplantation

Volumn 10, Issue 6, 2006, Pages 736-739

  Nalli, Nadya ^a   Stewart Teixeira, Lilian ^a   Dipchand, Anne I ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Amiodarone; Drug interaction; Heart transplant; Sirolimus; Tacrolimus

Indexed keywords

AMIODARONE; CYCLOSPORIN; GLYCOPROTEIN P; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NADOLOL; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ANEMIA; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CASE REPORT; DRUG BLOOD LEVEL; DRUG FEVER; DRUG METABOLISM; DRUG SAFETY; FEMALE; HEART VENTRICLE ARRHYTHMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; PRESCHOOL CHILD; STEADY STATE; TIME SERIES ANALYSIS; TREATMENT DURATION;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; DRUG INTERACTIONS; FATAL OUTCOME; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; SIROLIMUS; TACROLIMUS;

EID: 33746903483     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00561.x     Document Type: Article

References (19)

1. RUSSO LM, WEBBER SA. Pediatric heart transplantation: Immunosuppression and its complications. Curr Opin Cardiol 2004: 19: 104-109.
2. NOVARTIS Pharmaceuticals. Neoral (Cyclosporine) Product Monograph, 2003.
3. FUJISAWA. Prograf (Tacrolimus) Product Monograph, 2002.
4. WYETH. Rapamune (Sirolimus) Product Monograph. May 2004, Canada.
5. DRESSER GK, SPENCE JD, BAILEY DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000: 38: 41-57.
6. MICHALETS EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998: 18: 84-112.
7. DOHERTY MM, CHARMAN WN. The mucosa of the small intestine: How clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 2002: 41: 235-253.
8. WEST LJ, POLLOCK-BARZIV SM, DIPCHAND AI, et al. ABO-incompatible heart transplantation in infants. N Engl J Med 2001: 344: 793-800.
9. YAMREUDEEWONG W, DEBISSCHOP M, MARTIN LG, LOWER DL. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003: 26: 421-438.
10. LESKO LJ. Pharmacokinetic drug interactions with amiodarone. Clin Pharmacokinet 1989: 17: 130-140.
11. MAMPRIN F, MULLINS P, GRAHAM T, KENDALL S, et al. Amiodarone-cyclosporine interaction in cardiac transplantation. Am Heart J 1992: 123: 1725-1726.
12. CHITWOOD KK, BDUL-HAQQ AJ, HEIM-DUTHOY KL. Cyclosporine-amiodarone interaction. Ann Pharmacother 1993: 27: 569-571.
13. NICOLAU DP, UBER WE, CRUMBLEY AJ III, STRANGE C. Amiodarone-cyclosporine interaction in a heart transplant patient. J Heart Lung Transplant 1992: 11(3 Pt 1): 564-568.
14. BRATTSTROM C, SAWE J, TYDEN G, et al. Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther Drug Monit 1997: 19: 397-406.
15. SCHACHTER AD, MEYERS KE, SPANEAS LD, et al. Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. Pediatr Transplant 2004: 8: 171-177.
16. SCHUBERT M, VENKATARAMANAN R, HOLT DW, et al. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant 2004: 4: 767-773.
17. TEJANI A, ALEXANDER S, ETTENGER R, et al. Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis. Pediatr Transplant 2004: 8: 151-160.
18. MCDIARMID SV, COLONNA JO, SHAKED A, VARGAS J, AMENT ME, BUSUTTIL RW. Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. Transplantation 1993: 55: 1328-1332.
19. BOUCEK MM, EDWARDS LB, KECK BM, TRULOCK EP, TAYLOR DO, HERTZ MI. Registry for the International Society for Heart and Lung Transplantation: Seventh official pediatric report - 2004. J Heart Lung Transplant 2004: 23: 933-947.